

NEUROCURA



Non-invasive therapeutic to accelerate fracture healing

CLINICAL NEED

fractures per year in the United States

10-15%


are **delayed** or **nonunion** fractures

Up to 50%

are delayed or nonunion in patients with vascular damage or other comorbidities

Patient need for accelerated fracture healing as defined by Orthopedic Surgeon KOLs 80% (n = 10)60% 40% 20% 0% Hypertrophic non-union Oncologic co-morbidity Inflammatory disease Vascular damage Diabetes

PATIENT JOURNEY



Initial fracture

Acute fracture in long bone

Surgical fixation

Most fractures require surgical stabilization with plates or

Delayed healing & pain

intramedullary nails

Cases involving slow healing can be incredibly painful for patients

Reoperation

These nonunions can lead to reoperation



NEUROCURA

Accelerate fracture healing in patients who have delayed or non-union fractures and mitigate the pain associated with these fractures

COMPETITIVE ANALYSIS

PRODUCT	NON- INVASIVE	SINGLE DOSE	COST EFFECTIVE
NEUROCURA			
External Bone Stimulators			0
Parathyroid hormone			
Bone morphogenic proteins	O		O

OUR TEAM & KEY PARTNERSHIPS

MTM STUDENT TEAM

Arisa Chuklin Bryce Riffenburgh-Kirby Claire Bogosian Naveen Dhawan

MTM SPONSORS

Chelsea Bahney, PhD Tejal Desai, PhD Nafisa Elghazali, BS Chengbiao Wu, PhD

KEY PARTNER




OUR THERAPEUTIC



GROWTH FACTOR

stimulates cartilage and subsequent bone regrowth to accelerate fracture repair



MICRORODS

Growth factor is loaded onto microrods for localized, sustained release



INJECTABLE

Single-dose, non-invasive percutaneous injection at fracture site

REGULATORY PATHWAY

Innovation is a device + drug combination product. Primary mechanism of action is through the drug.



Preclinical studies/ IND-enabling studies •

IND submission -

Clinical Trials Phase I -> II -> III -

BLA submission •

...and finally, the patient's bedside!

Post market surveillance, explore other indications •

OPPORTUNITY & MARKET

TOTAL ADDRESSABLE

MARKET

Cost of nonunion fracture care in the US annually

\$38B

SERVICEABLE ADDRESSABLE MARKET

Bone growth stimulators market in the US annually

\$149.5M

SHARE OF MARKET

Percentage of market we expect to capture in five years

\$29.9M

